<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1543">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01982500</url>
  </required_header>
  <id_info>
    <org_study_id>CT/12.01</org_study_id>
    <nct_id>NCT01982500</nct_id>
  </id_info>
  <brief_title>Observation of Bevacizumab Plus Front-line Chemotherapy in Patients With Ovarian Cancer</brief_title>
  <official_title>A Multicentre, Observational Study of Bevacizumab (Avastin) Added to Front-line Chemotherapy in Patients With Stage IIIb, IIIC or IV Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma in Routine Clinical Practice.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Oncology Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hellenic Oncology Research Group</source>
  <oversight_info>
    <authority>Greece: National Organization of Medicines</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators propose to assess,the safety and tolerability profile (number of participants
      with adverse events) of bevacizumab (Avastin) when added to chemotherapy as front-line
      treatment of epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal
      carcinoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the last decade, clinical studies with bevacizumab (Avastin) in various tumors have shown
      encouraging results in terms of efficacy/safety. However there is no data generated in Greek
      population with regards to safety and efficacy of bevacizumab in front line Ovarian Cancer.
      Two prior  global phase III randomized trials showed that the addition of concurrent
      bevacizumab to standard chemotherapy and maintenance bevacizumab significantly increased the
      PFS in patients with advanced ovarian cancer It would be relevant to document the real life
      clinical data of bevacizumab in combination with chemotherapy (paclitaxel/carboplatin) in
      Front Line Ovarian Cancer as prescribed by the medical oncologists in Greece.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort</study_design>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Every 3 weeks up to 18 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>In this observational study investigators are going to assess standard schedules  in which administration was every 3 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Response Rate</measure>
    <time_frame>Disease evaluation at Week 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>In this observational study investigators are going to assess standard schedules in which the disease evaluation was performed every 3 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients with Progression Free Survival</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Overall Survival</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Avastin regimens</arm_group_label>
    <description>Patients who are going to receive chemotherapy plus Avastin (bevacizumab)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Clinics for cancer prevention
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Age ≥18 years

          -  Histologically confirmed advanced stage III (suboptimally debulked &gt;1cm of residual
             disease) or stage IV ovarian cancer fallopian tube carcinoma or primary peritoneal
             cancer following surgical debulking with the aim of maximal surgical cytoreduction

          -  One or more measurable lesions (≥1cm in diameter with spiral CT scan or ≥2cm    with
             conventional techniques) according to RECIST criteria

          -  ECOG performance status ≤2

          -  Adequate haematological, renal and hepatic function

          -  Urine protein &lt;2+ (dipstick)

          -  Life expectancy of &gt;12 weeks

        Exclusion Criteria:

          -  Previous front line treatment for ovarina cancer

          -  Previous radiotherapy to target lesions

          -  Patients with brain metastases and/or cancerous meningitis

          -  Presence or history of other neoplasm except properly treated basal cell skin cancer
             or in situ cervical carcinoma

          -  Patients participating in interventional clinical trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonia Kalykaki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hellenic Oncology Research Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vassilis Georgoulias, MD</last_name>
    <phone>+302810392750</phone>
    <email>georgulv@otenet.gr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Crete, Dep of Medical Oncology</name>
      <address>
        <city>Heraklion</city>
        <state>Crete</state>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Maragkoudaki</last_name>
      <phone>+302810392570</phone>
      <email>evamaragoud@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Antonia Kalykaki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Alexandroupolis, Dept. of Medical Oncology</name>
      <address>
        <city>Alexandroupolis</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stylianos Kakolyris, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Nikolaos Xenidis, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Stelios Kakolyris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Air Forces Military Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikos Fytrakis</last_name>
      <phone>2107715690</phone>
      <email>nikos251@yahoo.gr</email>
    </contact>
    <investigator>
      <last_name>Nikos Kentepozidis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;IASO&quot; General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stylianos Giassas, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stylianos Giassas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Metaxa's&quot; Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology</name>
      <address>
        <city>Piraeus</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolaos Ziras, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nikolaos Ziras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Theagenion&quot; Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ioannis Mpoukovinas, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ioannis Mpoukovinas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 6, 2013</lastchanged_date>
  <firstreceived_date>November 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Anti-angiogenic agent</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Front Line</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
